share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股sec公告 ·  06/11 16:20
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 06/11/2024, as per the latest filing. The shares, valued at approximately $96,762.82, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 85,896 Class A shares were sold by Borgeson, generating gross proceeds of $803,931.52. The upcoming sale reflects ongoing trading activity by the director, with the specific intent and plan for this sale having been adopted on 08/18/2023.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 06/11/2024, as per the latest filing. The shares, valued at approximately $96,762.82, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 85,896 Class A shares were sold by Borgeson, generating gross proceeds of $803,931.52. The upcoming sale reflects ongoing trading activity by the director, with the specific intent and plan for this sale having been adopted on 08/18/2023.
Recursion Pharmaceuticals, Inc.董事Blake Borgeson計劃於2024年6月11日出售11,447股A類股,根據最新提交的文件。這些股票的價值約爲96,762.82美元,最初是作爲發行人的補償的創始股份於2016年9月1日獲得的。這次計劃中的出售是在過去三個月中的一系列交易之後進行的,Borgeson已經出售了85,896股A類股,總成交額爲$803,931.52。未來的出售反映了該董事的持續交易活動,該銷售的具體意圖和計劃是在2023年8月18日提出的。
Recursion Pharmaceuticals, Inc.董事Blake Borgeson計劃於2024年6月11日出售11,447股A類股,根據最新提交的文件。這些股票的價值約爲96,762.82美元,最初是作爲發行人的補償的創始股份於2016年9月1日獲得的。這次計劃中的出售是在過去三個月中的一系列交易之後進行的,Borgeson已經出售了85,896股A類股,總成交額爲$803,931.52。未來的出售反映了該董事的持續交易活動,該銷售的具體意圖和計劃是在2023年8月18日提出的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息